Get started
RegeneRx Biopharmaceuticals, Inc.RegeneRx Biopharmaceuticals, Inc.RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials Ideas Discussions Technicals Seasonals

RGRX chart


Full chart

Key stats


Market capitalization
299.00 USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
—
Revenue (FY)
—
Shares float
‪836.25 K‬
Beta (1Y)
−92.47

About RegeneRx Biopharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
J. J. Finkelstein
Website
regenerx.com
Headquarters
Rockville
Founded
1982
FIGI
BBG000FW0B25
RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. Its product pipeline includes RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as RGRX.

Frequently Asked Questions


The current price of RGRX is 0.0002 USD — it hasn't changed in the past 24 hours. Watch RegeneRx Biopharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange RegeneRx Biopharmaceuticals, Inc. stocks are traded under the ticker RGRX.
RGRX stock hasn't changed in a week, the month change is a −85.71% fall, over the last year RegeneRx Biopharmaceuticals, Inc. has showed a −85.71% decrease.
RGRX reached its all-time high on Mar 23, 1987 with the price of 2,650.0000 USD, and its all-time low was 0.0002 USD and was reached on Oct 18, 2023. View more price dynamics on RGRX chart.
See other stocks reaching their highest and lowest prices.
RGRX stock is 0.00% volatile and has beta coefficient of −92.47. Track RegeneRx Biopharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is RegeneRx Biopharmaceuticals, Inc. there?
Yes, you can track RegeneRx Biopharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
No, RGRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RGRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade RegeneRx Biopharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So RegeneRx Biopharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating RegeneRx Biopharmaceuticals, Inc. stock shows the strong sell signal. See more of RegeneRx Biopharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.